Prosensa’s Hans Schikan Appointed to the Biotechnology Industry Organization’s Emerging Companies Section Governing Board

San Diego, CA, June 23, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA) the Dutch bio­phar­ma­ceu­ti­cal com­pa­ny focus­ing on rare dis­eases with a high unmet med­ical need, today announced that Hans GCP Schikan, Chief Executive Officer of Prosensa, has been appoint­ed to the Biotechnology Industry Organization’s (BIO) Emerging Companies Section Governing Board.
“As a glob­al expert in rare dis­eases and with invalu­able expe­ri­ence steer­ing a com­pa­ny from ear­ly stage through to a pub­licly list­ed com­pa­ny near­ing com­mer­cial­iza­tion, we wel­come Mr. Schikan to BIO’s board. His exper­tise in these areas, togeth­er with his pio­neer­ing expe­ri­ence in the Duchenne Muscular Dystrophy (DMD) space, will prove essen­tial as we con­tin­ue to work with reg­u­la­tors glob­al­ly to expe­dite treat­ment options for major unmet med­ical needs,” said Cartier Esham, BIO’s Executive Vice President of Emerging Companies.
In addi­tion to his role as Chief Executive Officer of Prosensa, Mr. Schikan also serves as Non-exec­u­tive Director of Swedish Orphan Biovitrum A.B., Executive Board Member of the Dutch Top Institute Pharma, and Member of the Core Team of the Dutch Top Sector Life Sciences & Health. He is also past Chairman of Nefarma, the Dutch Association of Research Based Pharmaceutical Industry.
“I am delight­ed to be join­ing the BIO Emerging Companies Section Governing Board and work along­side oth­er indus­try lead­ers to con­tin­ue to advance the biotech­nol­o­gy indus­try”, said Mr. Schikan.
“BIO’s work is cru­cial to help­ing emerg­ing com­pa­nies thrive in this chal­leng­ing space. The work BIO has accom­plished in recent years with sig­nif­i­cant con­tri­bu­tions to the JOBS Act and FDASIA have enabled inno­va­tors like Prosensa to more eas­i­ly access the cap­i­tal mar­kets and work more col­lab­o­ra­tive­ly with reg­u­la­tors. I look for­ward to draw­ing from my expe­ri­ence to con­tin­ue to pro­mote inno­va­tion for the ben­e­fit of patients and indus­try,” he said.

Notes to edi­tors
About Hans GCP Schikan, Chief Executive Officer
Hans Schikan, 55, has served as Chief Executive Officer of Prosensa N.V. since January 2009. Mr. Schikan has more than 25 years of senior man­age­r­i­al expe­ri­ence in the phar­ma­ceu­ti­cal and biotech­nol­o­gy indus­tries. From May 2004 until January 2009, Mr. Schikan worked at Genzyme Corporation in var­i­ous exec­u­tive roles, includ­ing Vice President of Global Marketing and Strategic Development for its rare genet­ic dis­ease fran­chise. In this posi­tion he over­saw the launch of var­i­ous orphan drugs glob­al­ly. Prior to Genzyme, Mr. Schikan worked at Organon International from 1986 to 2004 in var­i­ous senior busi­ness roles across dif­fer­ent geo­gra­phies, includ­ing man­ag­ing direc­tor posi­tions in mul­ti­ple coun­tries. Mr. Schikan also serves as Non-exec­u­tive Director of Swedish Orphan Biovitrum A.B., Executive Board Member of the Dutch Top Institute Pharma, and Member of the Core Team of the Dutch Top Sector Life Sciences & Health. He is also past Chairman of Nefarma, the Dutch Association of Research Based Pharmaceutical Industry. Mr. Schikan holds a Pharm.D. degree from the University of Utrecht, the Netherlands.

Leave a Reply

Your email address will not be published. Required fields are marked *